- Zoetis has launched Lenivia (izenivetmab injection) in Canada and EU member states, offering up to three months of osteoarthritis pain management with a single subcutaneous injection.
- The long-acting monoclonal antibody targets nerve growth factor (NGF), a mediator of pain and inflammation, and binds to a different site on NGF than currently marketed anti-NGF monoclonal antibodies.
- In a pivotal nine-month European field study, Lenivia demonstrated sustained pain reduction, with effects observed as early as Day 7 after the first injection. The therapy is designed to provide longer-lasting pain control and improve treatment convenience and compliance.
- With up to 40% of dogs showing radiographic evidence of osteoarthritis, Lenivia expands Zoetis’ canine OA pain portfolio alongside Rimadyl, Trocoxil, and Librela, offering veterinarians another option for long-term, individualized pain management.
Takeaways:
Lenivia’s launch in Canada and the EU adds a three‑month, injectable biologic into Zoetis’ canine OA toolkit, which is likely to shift more chronic pain management away from daily NSAIDs toward long‑acting monoclonal antibodies, deepen Zoetis’s share of the fast‑growing veterinary mAb segment, and increase practice and owner loyalty through convenient quarterly dosing in a market where up to 40% of dogs show radiographic osteoarthritis.
Source: Businesswire
